| Renee Batt Counseling Llc | |
|
44 S Broad St Hillsdale MI 49242-1847 | |
| (517) 425-8118 | |
| Not Available |
| Full Name | Renee Batt Counseling Llc |
|---|---|
| Speciality | Social Worker |
| Location | 44 S Broad St, Hillsdale, Michigan |
| Authorized Official Name and Position | Renee C Batt (OWNER) |
| Authorized Official Contact | 5174258118 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Renee Batt Counseling Llc 1212 Meadow Ln Hillsdale MI 49242-8712 Ph: (517) 425-8118 | Renee Batt Counseling Llc 44 S Broad St Hillsdale MI 49242-1847 Ph: (517) 425-8118 |
| NPI Number | 1669914057 |
|---|---|
| Provider Enumeration Date | 11/16/2016 |
| Last Update Date | 11/16/2016 |
| Medicare PECOS PAC ID | 6507147436 |
|---|---|
| Medicare Enrollment ID | O20170106001592 |
News Archive
To coincide with Rare Disease Day 2015, the Consortium of Eosinophilic Gastrointestinal Disease Researchers today launched a patient contact registry for individuals with eosinophilic gastrointestinal diseases (EGID), a group of rare diseases.
Epocrates, Inc., a leading provider of mobile drug reference tools and interactive services to healthcare professionals and the healthcare industry, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.
Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669914057 | NPI | - | NPPES |
| 1041C0700X | Other | TAXONOMY - CLINICAL SOCIAL WORKER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 104100000X | Social Worker | 6801087177 (Michigan) | Primary |
| Provider Name | Renee C Batt |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1255654869 PECOS PAC ID: 7214218148 Enrollment ID: I20170106001669 |
News Archive
To coincide with Rare Disease Day 2015, the Consortium of Eosinophilic Gastrointestinal Disease Researchers today launched a patient contact registry for individuals with eosinophilic gastrointestinal diseases (EGID), a group of rare diseases.
Epocrates, Inc., a leading provider of mobile drug reference tools and interactive services to healthcare professionals and the healthcare industry, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.
Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
› Verified 7 days ago
News Archive
To coincide with Rare Disease Day 2015, the Consortium of Eosinophilic Gastrointestinal Disease Researchers today launched a patient contact registry for individuals with eosinophilic gastrointestinal diseases (EGID), a group of rare diseases.
Epocrates, Inc., a leading provider of mobile drug reference tools and interactive services to healthcare professionals and the healthcare industry, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.
Bayer Inc. today responded to Professor Marvin Meyer's letter to the editor, entitled: "Critical questions concerning the validity of the Bayer study report of differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration" and published in the online edition of the International Journal of Clinical Pharmacology and Therapeutics. Bayer responded to the clinical relevance of the differences in formulation and dissolution behaviour and the delayed absorption of Mylan's extended release nifedipine.
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
› Verified 7 days ago
A New Beginning Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 104 Hillsdale St, Hillsdale, MI 49242 Phone: 517-425-4975 | |
Ula Sky Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 11 E Carleton Rd, Hillsdale, MI 49242 Phone: 517-921-8627 | |
Hillsdale Psychological Institute Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 37 Waldron St, Hillsdale, MI 49242 Phone: 517-439-4596 Fax: 517-439-4597 | |
Samantha Corey Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 263 Industrial Dr, Hillsdale, MI 49242 Phone: 517-826-5242 Fax: 517-826-5246 | |
Family Counseling Center, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 11 E Carleton Rd, Hillsdale, MI 49242 Phone: 517-437-7100 Fax: 517-437-7101 | |
Hillsdale College Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 33 E. College St, Hillsdale, MI 49242 Phone: 517-437-7341 Fax: 517-607-2222 | |
Barb Corbett, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 55 Barry St, Hillsdale, MI 49242 Phone: 517-437-5538 Fax: 517-427-5538 |